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In the present study we describe the isolation and functional analysis of a sphingolipid biosynthetic gene,
IPT1, of Candida albicans. The functional consequence of the disruption of both alleles of IPT1 was confirmed
by mass analysis of its sphingolipid composition. The disruption of both alleles or a single allele of IPT1 did
not lead to any change in growth phenotype or total sphingolipid, ergosterol, or phospholipid content of the
mutant cells. The loss of mannosyl diinositol diphosphoceramide [M(IP)2C] in the ipt1 disruptant, however,
resulted in increased sensitivity to drugs like 4-nitroquinoline oxide, terbinafine, o-phenanthroline, flucon-
azole, itraconazole, and ketoconazole. The increase in drug susceptibilities of ipt1 cells was linked to an altered
sphingolipid composition, which appeared to be due to the impaired functionality of Cdr1p, a major drug efflux
pump of C. albicans that belongs to the ATP binding cassette superfamily. Our confocal and Western blotting
results demonstrated that surface localization of green fluorescent protein-tagged Cdr1p was affected in ipt1
disruptant cells. Poor surface localization of Cdr1p resulted in an impaired ability to efflux fluconazole and
rhodamine 6G. The effect of mannosyl inositol phosphoceramide accumulation in the ipt1 mutant and the
absence of M(IP)2C from the ipt1 mutant on the efflux of drug substrates was very selective. The efflux of
methotrexate, a specific substrate of CaMdr1p, another major efflux pump of major facilitator superfamily,
remained unaffected in ipt1mutant cells. Interestingly, changes in sphingolipid composition affected the ability
of mutant cells to form proper hyphae in various media. Taken together, our results demonstrate that an
altered composition of sphingolipid, which is among the major constituents of membrane rafts, affects the drug
susceptibilities and morphogenesis of C. albicans.
The early steps in mammalian and fungal sphingolipid syn-
thesis are conserved, but finally, they diverge to produce struc-
turally and chemically different types of sphingoid bases, cer-
amides, and complex sphingolipids (12). Therefore, over the
years, the sphingolipid biosynthetic pathway has been ex-
ploited as an antifungal drug target in pathogenic yeasts (24,
29). Unlike mammals, fungi do not have phosphatidylcholine
as part of their polar head group in the sphingolipids; instead,
they have phosphoinositol, which is transferred by Aur1p to
the C-1 hydroxyl of ceramide to make inositol phosphoceram-
ide (IPC) (6, 7). IPC is further modified by the addition of
mannose by Csg1p, Csg2p, and Vrg4p to make mannosyl ino-
sitol phosphoceramide (MIPC) and the addition of a second
inositol phosphate group by Ipt1p to make mannosyl diinositol
diphosphoceramide [M(IP)2C] (6, 7). The biosynthesis of
sphingolipids starts in the endoplasmic reticulum and proceeds
up to the formation of ceramides (12). Subsequently, complex
fungal sphingolipids [IPC, MIPC, and M(IP)2C] are synthe-
sized in the Golgi apparatus. Recent reports have suggested
that the biosynthesis of these sphingolipids is critical to the
maintenance of plasma membrane (PM) function; however,
the synthesis of M(IP)2C is not critical for viability (8). In
Saccharomyces cerevisiae, ipt1 deletion mutants grow normally
but display sensitivity to calcium and increased resistance to
the polyene antibiotic nystatin (7, 23). Moye-Rowley and his
group have observed that the loss of IPT1 has complex effects
on drug resistance in S. cerevisiae, mediated through Pdr1p and
Pdr3p transcription factors which regulate multidrug resistance
genes in S. cerevisiae (15).
Candida albicans is an opportunistic diploid fungus that
causes superficial as well as systemic infections in immunocom-
promised and debilitated patients (5). Unlike in S. cerevisiae,
the regulation of synthesis of sphingolipids and their roles in
membrane function in C. albicans cells are not well under-
stood. In order to explore the role of sphingolipids, we had
earlier used a specific inhibitor, fumonisin B1, which blocks the
synthesis of phytoceramide, a precursor of the three major
sphingolipid species (28). We observed a close interaction be-
tween plasma membrane ergosterol and sphingolipids in C.
albicans cells (28), wherein the depletion of either of the two
resulted in the impaired functionality of a major drug efflux
pump, Cdr1p, and as a consequence turned Candida cells hy-
persensitive to several drugs. In this study we have specifically
blocked the synthesis of M(IP)2C by homozygous disruption of
the IPT1 gene, which mediates the conversion of MIPC to
M(IP)2C. This provided an opportunity to analyze the role of
M(IP)2C, which accounts for the majority of membrane sphin-
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golipids. We observed that the specific accumulation of MIPC
in ipt1 disruptants increased sensitivity to several drugs. Inter-
estingly, the ipt1 mutant cells also showed defects in their
ability to form hyphae in different media.
MATERIALS AND METHODS
Materials. Medium chemicals were obtained from Difco (Detroit, Mich.) and
HiMedia (Mumbai, India), and lipid N-rhodamine-dioleoyl-phosphatidylethano-
lamine was purchased from Avanti Polar Lipids Inc. (Albaster, Ala). Sigma
Chemical Co. (St. Louis, Mo.) was the source of L-dipalmitoyl-phosphatidylcho-
line and rhodamine 6G (R6G); the drugs 4-nitroquinoline oxide, terbinafine,
o-phenanthroline, nystatin, amphotericin B, cycloheximide, and methotrexate; as
well as protease inhibitors (phenylmethylsulfonyl fluoride, leupeptin, pepstatin
A, and aprotinin). Nourseothricin was obtained from Werner Bioagents (Jena,
Germany). Fluconazole was a kind gift from Ranbaxy Laboratories (New Delhi,
India), while sulfomethuron methyl, ketoconazole, and itraconazole were gifts
from Du Pont (Wilmington, Del.). [3H]fluconazole ([3H]FLU) was custom pre-
pared by Amersham, United Kingdom. [3H]methotrexate ([3H]MTX) was pro-
cured from Amersham. Labeled 6-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino
hexanoyl] sphingosylphosphocholine (NBD-sphingomyelin [NBD-SPH]) was
purchased from Molecular Probes (Eugene, Oreg.).
Bacterial and yeast strains and growth media. C. albicans strain SC5314 was
procured from the American Type Culture Collection. Escherichia coli was cul-
tured in Luria-Bertani medium (Difco, BD Biosciences), to which ampicillin was
added (100 g/ml). The Candida strains were cultured in YEPD (yeast extract-
peptone-dextrose) broth (Bio 101, Vista, CA) or Sabouraud dextrose broth
without uracil (SD-URA, minimal defined media SDU consisting of 2%
glucose supplemented with yeast nitrogen base; Bio 101), as required. For agar
plates, 2% (wt/vol) Bacto Agar (Difco, BD Biosciences) was added to the me-
dium. The strains and plasmids used in this study are listed in Table 1. Strains
CAF2-1, TPIPT1-1, TPIPT1-3, and TPIPT1-5 were used for all functional assays
and are referred to as the wild type (WT), the heterozygous disruptant, the
homozygous disruptant, and the heterozygous revertant, respectively. Cdr1p of
CAF2-1, TPIPT1-1, TPIPT1-3, and TPIPT1-5 was tagged with green fluorescent
protein (GFP); and the respective strains were designated TPWT-GFPCDR1,
TPD1-GFPCDR1, TPD2-GFPCDR1, and TPR1-GFPCDR1.
Construction of disruption cassette pTPIPT1-HUH. The IPT1 open reading
frame (ORF) was amplified from the genomic DNA of C. albicans strain SC5314
by using the primers IPT1F (5-GTGGTTTACCTTTAGGGTGGTTG-3) and
IPT1R (5-GGTGGGTGGTGGGTGGTGTTT-3) and Pfu Turbo (Stratagene).
This amplicon was then cloned into the EcoRV site of pBSK-S/X (Table 1),
yielding pTPIPT1. For the construction of the URA blaster cassette, plasmid
pMB-7 (10), which harbors the C. albicans URA3 gene flanked by Salmonella
serovar Typhimurium hisG DNA, was digested with BamHI and BglII, yielding
a 4.044-kb fragment which was subsequently cloned into plasmid pUC19 to get
the desired restriction sites, yielding pTPHUH. From pTPHUH, a 4.061-kb
SalI-SmaI fragment containing hisG-Ura3-hisG was then inserted into pTPIPT1
at SalI-HpaI, yielding the disruption cassette pTPIPT1-HUH. The SacI-KpnI-
digested 4.866-kb fragment of pTPIPT1-HUH was used to disrupt IPT1 in
Candida wild-type strain CAI-4 (Fig. 1A and B).
Construction of reintegration cassette pTPIPT1R. A 2.441-kb fragment ob-
tained by EcoRV digestion of pTPIPT1-HUH was cloned at the HpaI site of
pTPIPT1 located downstream of the CaIPT1 ORF, yielding pTPIPT1R (Fig.
1C). A 5.157-kb SacI-KpnI fragment from pTPIPT1R was used to transform the
homozygous ipt1 mutant strain, TPIPT1-4, for the construction of heterozygous
revertant strain TPIPT1-5, which had one functional IPT1 allele and the URA3
gene as a marker.
Construction of pCPG2. Plasmid vector pCPG2 was constructed to fuse GFP
with the CDR1 ORF at its own locus by mutating its stop codon into a BamHI
site. This 250 bp of the C-terminal CDR1 ORF was PCR amplified by using
primers CDR29F (5-ATTTGGTACCATACATTAAATTTGCTGGTGGG-3)
and CDR30R (5-GTTTGGATCCTTTCTTATTTTTTTTCTCTCTGTTACCC-
3). The PCR amplicon was digested with KpnI-BamHI (the sites were intro-
duced into the forward and the reverse primers during synthesis). GFP, along
with ACT1 termination sequence and dominant selection marker gene SAT1, was
taken out by digesting vector pADH1G3 with BamHI-PstI. The KpnI-PstI-
digested vector backbone of pCPL51 (2.9 kb) was ligated with the KpnI-BamHI-
digested C terminus of CDR1 along with the BamHI-PstI-digested GFP-SAT1
fragment to generate the final clone, pCPG2 (6.5 kb). The KpnI-SacII restriction
sites were used to take out the linearized cassette (CT-CDR1-GFP-SAT1-3
untranslated region) from plasmid pCPG2 and transformed into the C. albicans
wild-type and the IPT1 disruptant and heterozygous revertant strains to produce
strains with GFP-tagged Cdr1p.
TABLE 1. Strains and plasmids used in this study
Plasmid or strain Description or genotype Source or reference
Plasmids
pBKS Bluescript II KS vector Stratagene
pBSK-S/X Bluescript II KS vector with SalI and XhoI sites removed and then religated This study
pTPIPT1 2.614-kb amplicon containing IPT1 inserted into pBKS-S/X at EcoRV This study
pUC19 Small, high-copy-number plasmid MBI, Fermentas
pMB7 Plasmid that contains the C. albicans URA3 gene flanked by 1.1-kb direct repeats of the
Salmonella enterica serovar Typhimurium hisG DNA
10
pTPHUH 4.044-kb BamHI-BglII fragment from pMB7 containing hisG-Ura3-hisG inserted into
pUC19 at BamHI
This study
pTPIPT1R 4.061-kb SalI-SmaI fragment from pTPHUH containing hisG-Ura3-hisG inserted into
pTPIPT1 at SalI-HpaI
This study
pADH1G3 Plasmid harboring the SAT1 and GFP genes 26
pCPL51 Plasmid harboring CDR1-LACZ fusion with 3 CDR1 This study
pCPG2 Bluescript II KS vector containing a 3.5-kb fragment, GFP fused to the C terminus of
CDR1 by mutating stop codon into BamHI, along with CaSAT1 marker gene
This study
C. albicans strains
SC 5314 URA3/URA3 10
CAF2-1 URA3/ura3::imm434 10
CAI4 ura3::imm434/ura3::imm434 10
TPIPT1-1 ura3::imm434/ura3::imm434 IPT1/ipt1::hisG-URA3-hisG This study
TPIPT1-2 ura3::imm434/ura3::imm434 IPT1/ipt1::hisG This study
TPIPT1-3 ura3::imm434/ura3::imm434 ipt1::hisG-URA3-hisG/ipt1::hisG This study
TPIPT1-4 ura3::imm434/ura3::imm434 ipt1::hisG/ipt1::hisG This study
TPIPT1-5 ura3::imm434/ura3::imm434 ipt1::hisG/ipt1::hisG::IPT1-URA3 This study
TPWT-GFPCDR1 URA3/ura3::imm434 This study
TPD1-GFPCDR1 ura3::imm434/ura3::imm434 IPT1/ipt1::hisG-URA3-hisG This study
TPD2-GFPCDR1 ura3::imm434/ura3::imm434 ipt1::hisG-URA3-hisG/ipt1::hisG This study
TPR1-GFPCDR1 ura3::imm434/ura3::imm434 ipt1::hisG/ipt1::hisG::IPT1-URA3 This study
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DNA and RNA isolation and hybridization. Yeast genomic DNA was isolated
as described elsewhere (1). A total of 5 g of genomic DNA from each trans-
formant and the WT cells was digested with SalI and electrophoresed for South-
ern analyses. Southern hybridizations were carried out with the 1.716-kb SacI-
NdeI fragment, which was used as the probe and which was derived from
N-terminal region of pTPIPT1. Total RNA were isolated and Northern blot
analyses were done essentially by standard protocols, as described before (1, 22,
31). Equal loading of RNA was checked by detection of equal intensity of the
rRNA bands, and the relative intensities of the CDR1 mRNA signals in Northern
hybridizations were quantitated in an FLA5000 Fuji phosphoimager.
Candida transformation. The lithium acetate method was used for the trans-
formation of C. albicans cells, as described previously (13). Transformants were
selected on synthetic minimal medium (Sabouraud dextrose medium) to obtain
Ura transformants, and these Ura transformants were cured of Ura by the use
of 5-fluoroorotic acid (1 mg/ml) and 25 g/ml uridine.
Strains CAF2-1, TPIPT1-1, TPIPT1-3, and TPIPT1-5 were transformed with a
linearized 3.5-kb KpnI-SacII fragment from plasmid pCPG2 to produce strains
TPWT-GFPCDR1, TPD1-GFPCDR1, TPD2-GFPCDR1, and TPR1-GFPCDR1
with GFP-tagged Cdr1p, respectively. The transformants were selected on YEPD
plates containing 200 g/ml of nourseothricin.
Detection of sphingolipids by mass spectrometry. Sphingolipids were ex-
tracted by following a protocol used for S. cerevisiae described earlier by Take-
moto and colleagues (33). Negative-ion mass electrospray spectra were recorded
on a liquid chromatography-time of flight mass spectrometer (Micromass-Wa-
ters). The spectral data were analyzed with MassLynx software. The m/z range
was recorded to be from 500 to 1,500 Da. A constant flow of the solvent
chloroform-methanol-water (16:16:5 vol/vol/vol) was maintained with a pump
connected to the spraying capillary. Solutions of extracted sphingolipids in the
solvent described above were injected into the solvent flow of the above liquid
chromatograph-mass spectrometer for analysis.
Drug efflux assay. The glucose-induced efflux of fluorescent R6G and radio-
labeled [3H]FLU (specific activity, 19 Ci/mmol) was carried out essentially as
described in our earlier publications (21, 28). R6G and [3H]FLU were used to
final concentrations of 10 M and 100 nM, respectively. MTX transport was
determined as described earlier (20). [3H]MTX (specific activity, 5.7 Ci/mmol)
was added to a final concentration of 25 M.
Labeling of cells with NBD-SPH. Labeling of cells with NBD-SPH was carried
out essentially as described earlier (28).
Morphogenetic studies on solid and liquid media. Studies of hyphal induction
by wild-type and mutant cells of C. albicans were carried out on solid Spider (1%
FIG. 1. Schematic representation of the disruption and complementation of IPT1 using the URA3 selection marker. (A) Diagrammatic
representation of the disruption cassette derived from pTPIPT1-HUH containing hisG-URA3-hisG with flanking portions (regions between
positions 1785 and 2039 and positions 4039 and 4399) on either side for homologous recombination. (B) Sequential targeted disruption of the two
IPT1 alleles in C. albicans with the disruption cassette. Strain designations are shown on the right. (C) Schematic representation of the
reintegration cassette used for reintroduction of one wild-type IPT1 allele and genomic reintegration of an intact copy into TPIPT1-4 by using the
reintegration cassette pTPIPT1R, which led to revertant strain TPIPT1-5. (D) Southern analysis of the genomic DNA digested with SalI. Lanes:
1, CAI4; 2, TPIPT1-1; 3, TPIPT1-2; 4, TPIPT1-3; 5, TPIPT1-4; 6, TPIPT1-5. The hybridization probe was the 1.716-kb SacI-NdeI fragment derived
from N-terminal region of pTPIPT1 (Table 1). The exact size and genotype of the expected hybridizing DNA fragment are indicated on the left.
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nutrient broth, 1% mannitol, 0.2% K2HPO4, 2% Bacto Agar) and nitrogen
starvation SLAD (0.17% yeast nitrogen base without amino acids and ammo-
nium sulfate, 2% glucose, 50 M ammonium sulfate, 2% Bacto Agar) medium
plates and with 10% bovine calf serum in liquid YEPD and 2.5 mM N-acetyl-
D-glucosamine in liquid salt base medium (containing 0.45% NaCl and 0.335%
yeast nitrogen base without amino acids), as described elsewhere (2, 3, 19, 35).
Nucleotide sequence accession number. The IPT1 ORF amplified from the
genomic DNA of C. albicans SC5314 with primers IPT1F and IPT1R has been
submitted to GenBank and has been given accession number AY884203.
RESULTS
Identification and homozygous disruption of CaIPT1.
BLAST analysis revealed one gene in the C. albicans genome
that bore significant homology (expected value  3e-36) with
S. cerevisiae ScIPT1, which encodes inositol phosphoryl trans-
ferase, and was designated CaIPT1 (orf 6.927). CaIPT1 also
shows similarity to another sphingolipid biosynthetic gene of S.
cerevisiae, AUR1 (expected value  1e-24) and CaAUR1 of C.
albicans (expected value  1e-24) (Fig. 2A), which performs a
similar function of adding an inositol phosphate group, as
predicted by homology to ScAUR1 (18). The 1,545-bp CaIPT1
gene is located on chromosome I. The Stanford contig 6-1754
has the CaIPT1 sequence from positions 2266 to 3810. The
estimated molecular mass of the putative membrane protein
CaIpt1p (514 amino acids) is 59.43 kDa.
The IPT1 ORF was amplified from the genomic DNA of C.
albicans SC5314 with primers IPT1F and IPT1R (see Materials
and Methods) and sequenced (GenBank accession number
AY884203). As described in Materials and Methods, the URA
blaster cassette was used for homozygous disruption of CaIPT1
(10). Both IPT1 alleles were sequentially disrupted by using the
disruption cassette (Fig. 1A). Strains TPIPT1-2 and TPIPT1-4
were obtained by looping out the URA3 gene from TPIPT1-1
and TPIPT1-3, respectively (Fig. 1B). To obtain heterozygous
revertant strain TPIPT1-5, which has one functional IPT1 al-
FIG. 2. (A) Schematic representation of the sphingolipid biosynthetic pathway in fungi. AUR1 encodes IPC synthase; CSG1, CSG2, and VRG4
add mannose to IPC (possible mannosyltransferases); and IPT1 encodes inositol phosphotransferase. (B) Mass spectrometric analysis of sphin-
golipids. Negative-ion mass spectra of the m/z range of 500 to 1,500 Da of the sphingolipids extracted from the WT and homozygous IPT1 mutant
strain TPIPT1-3. The positions of the respective three prominent sphingolipid species are indicated as follows: for IPC, 952.7 [M-H], 966.7
[M-H], and 980.7 [M-H]; for MIPC, 1,114.7 [M-H] and 1,142.7 [M-H]; and for M(IP)2C, 677.9 [M-2H]
2 and 691.9 [M-2H]2 for doubly
charged ions and 1,355.8 [M-H] and 1,383.8 [M-H] for ions with a single charge. (C) Enlarged negative-ion mass spectra of the m/z range of
1,300 to 1,500 Da of the sphingolipids extracted from the WT and homozygous IPT1 mutant strain TPIPT1-3 to show the absence of the M(IP)2C
peak at the indicated position for TPIPT1-3, unlike the WT strain.
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lele, homozygous disruptant mutant TPIPT1-4 was trans-
formed with the SacI-KpnI fragment of pTPIPT1R (Table 1;
Fig. 1C). Strains CAF2-1 (wild type), TPIPT1-1 (heterozygous
disruptant), TPIPT1-3 (homozygous disruptant), and TPIPT1-5
(heterozygous revertant) were used for all functional assays (Ta-
ble 1). Correct insertion of the disruption cassette was checked by
Southern analysis (Fig. 1D). Two independent clones were picked
and analyzed simultaneously. Pairs of isogenic mutant strains
were identical in all phenotypes (data not shown).
Sphingolipid compositions of ipt1 mutants. The disruption
of CaIPT1 was further confirmed by sphingolipid analysis of
the mutant and WT cells by using mass spectrometric analysis.
The mass analysis of the extracted sphingolipids of WT Can-
dida cells indicated three major peaks for sphingolipid species:
for IPC, singly charged species [M-H] at m/z  952.7, 966.7,
and 980.7 Da; for MIPC, singly charged molecular ions
[M-H] at m/z  1,114.7 and 1,142.7 Da, and for M(IP)2C,
mass spectrum showed signals at m/z  677.9 and 691.9 Da for
doubly charged molecular species [M-2H]2 and at m/z 
1,355.8 and 1,383.8 Da for singly charged molecular ions
[M-H] (Fig. 2B and C). The observed mass difference of 162
Da between IPC and MIPC confirmed the expected difference
due to the additional mannose group in MIPC. The observed
difference in mass of 241.1 Da between MIPC and M(IP)2C is
due to the additional inositolphosphate group in M(IP)2C. The
mass spectra of the three sphingolipids showed signals for two
to four species of the sphingolipids which could be attributed
to heterogeneity in the number of OCH2 groups, since IPC,
MIPC, and M(IP)2C have different fatty acid chain lengths that
vary from 22 to 26 and the presence of the abundant long chain
bases as C18 or C20 phytosphingosines (17, 36) (Fig. 2). Unlike
the wild-type Candida cells, homozygous mutant TPIPT1-3
FIG. 3. Drug resistance profiles of the C. albicans wild type and IPT1 mutants determined by the broth microdilution assay (A) and spot assay
(B), which were done as described previously (27, 28). The MIC80 (defined as the lowest drug concentration that gave 80% inhibition of growth
compared to the growth of the drug-free controls) was determined by the broth microdilution method and was evaluated both visually and by
reading the absorbance at 620 nm in a microplate reader. In the spot assay, 5 l of fivefold serial dilutions of each yeast culture (A600  0.1) was
spotted onto YEPD plates in the absence (control) and the presence of the following drugs: 4-nitroquinoline oxide (0.1 g/ml), terbinafine (0.2
g/ml), o-phenanthroline (8 g/ml), fluconazole (0.1 g/ml), itraconazole (0.01 g/ml), ketoconazole (0.01 g/ml), nystatin (1.5 g/ml), ampho-
tericin B (0.5 g/ml), cycloheximide (4 mg/ml), sulfomethuron methyl (20 g/ml), and methotrexate (4 g/ml). Growth differences were evaluated
by using drug-free controls following incubation of the plates for 48 h at 30°C. 4-Nitroquinoline oxide, terbinafine, o-phenanthroline, fluconazole,
itraconazole, ketoconazole, nystatin, cycloheximide, and sulfomethuron methyl are known substrates of CDR1; and methotrexate is a well-known
substrate of CaMDR1 (20, 21, 27, 32).
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cells revealed a total absence of M(IP)2C, indicated by the
absence of the mass spectrum peak at m/z  691.5 [M-2H]2
as well as at 1,383.8 [M-H] and 1,355 [M-H] and showed,
instead, an increased area of the peak for MIPC.
Of note, the variations in the sphingolipid compositions of
the TPIPT1-3 mutant and its heterozygous counterpart
(TPIPT1-1) resulted in no significant changes in cell growth
when they were grown on rich medium like YEPD com-
pared to that of the WT cells (data not shown). There was
no major change in the total phospholipid, sphingolipid, or
ergosterol contents of TPIPT1-1 and TPIPT1-3 cells (data
not shown).
IPT1mutants of C. albicans are susceptible to various drugs.
As mentioned above, since the homozygous disruption of
IPT1 led to the specific accumulation of MIPC without sig-
nificantly affecting the total contents of sphingolipids and
other phospholipids, we examined if the loss of M(IP)2C
could in any way affect the drug susceptibilities of ipt1 mu-
tants. The results of the drug susceptibility tests by two
independent methods, MIC (MIC80) and spot assays, dem-
onstrated that the ipt1 mutants were susceptible to 4-nitro-
quinoline oxide, terbinafine, and o-phenanthroline and to
the azoles tested, which included fluconazole, itraconazole,
and ketoconazole (Fig. 3A and B). Although the spot assay
revealed that these mutants were additionally sensitive to
cycloheximide and sulfomethuron methyl, there was no
change in the MIC80 values between the mutant and WT
cells for these drugs (Fig. 3A and B). The discrepancy be-
tween the results of the MIC assay and that of the spot assay
is not surprising, since in many instances such differences
between various drug susceptibility assays have been re-
ported previously (9, 27, 28). We also checked the suscep-
tibilities of the ipt1 mutant cells to two well-known polyenes,
namely, nystatin and amphotericin B. Interestingly, both
spot assay and MIC80 values revealed that ipt1 mutants were
resistant to polyenes (Fig. 3A and B).
FIG. 4. (A) Glucose-induced R6G efflux from C. albicans cells. The protocol of the efflux assay has been described in our earlier publication
(28). To achieve deenergization of exponentially grown Candida cells for depletion of the intracellular ATP, cells were resuspended in deener-
gization buffer (phosphate-buffered saline without glucose and with 5 mM deoxyglucose and 5 mM dinitrophenol) at a cell density of 108 cells ml1.
R6G was then added to the cell suspension to a final concentration of 10 M, and the mixture was incubated for 2 h at 30°C. Efflux was initiated
by addition of 2% glucose, and the absorption of the extruded dye in the supernatant was measured at 527 nm. Open bars, extracellular
concentration of R6G at 30 min after the addition of glucose. The values are the means standard deviations (indicated by the error bars) of three
independent experiments. (B) Intracellular concentration of [3H]FLU in deenergized C. albicans WT and IPT1 mutant strains 30 min after
glucose-induced drug efflux. The values indicated by the bars represent the means  standard deviations (indicated by the error bars) of three
independent experiments. (C) Intracellular concentration of [3H]MTX in C. albicans WT and IPT1 mutant strains at 45 min. The values indicated
by the bars represent the means  standard deviations (indicated by the error bars) of three independent experiments.
VOL. 49, 2005 SPHINGOLIPIDS IN CANDIDA RESISTANCE AND MORPHOGENESIS 3447
Enhanced drug sensitivity of IPT1 mutants is associated
with reduced efflux of substrates. Since the ipt1 mutant cells
were found to be susceptible to drugs which are also substrates
of Cdr1p, a major drug efflux pump belonging to the ATP
binding cassette (ABC) superfamily of transporters, we
checked the functionality of this pump. R6G and FLU are
well-known substrates of Cdr1p and were earlier used to mon-
itor the drug efflux activity of Cdr1p (28). Fluorescent R6G
and [3H]FLU were allowed to equilibrate in deenergized Can-
dida cells by passive diffusion, and the energy-dependent ex-
trusion of R6G was then initiated by the addition of glucose.
As depicted in Fig. 4A, after glucose addition, a decrease in the
extracellular concentration (due to low efflux) of R6G was
observed in TPIPT1-1 and TPIPT1-3 mutant cells compared to
that in the WT cells, which clearly indicated impaired efflux
activity by the mutant cells. That the efflux ability of TPIPT1-3
mutant cells was reduced was further confirmed by using an-
other substrate, [3H]FLU. The efflux of equilibrated [3H]FLU
in deenergized cells also was initiated by the addition of glu-
cose. As shown in Fig. 4B, the intracellular levels of accumu-
lation of [3H]FLU were higher (due to low levels of efflux) in
the mutant cells than in the WT cells. Of note, deenergized ipt1
cells also showed increased passive diffusion of drugs (data not
shown). This would mean that enhanced passive entry could
also increase the intracellular concentration of the drug, which
may contribute to the observed changes in the drug suscepti-
bilities of ipt1 cells.
Variations in sphingolipid composition selectively affect
Cdr1p functioning. CaMdr1p, which is a member of major
facilitator superfamily (MFS) of proteins, is another drug ex-
trusion pump whose upregulation has been linked to azole
resistance in C. albicans (11, 14, 37, 38). We had earlier ob-
FIG. 5. (A) Immunodetection of Cdr1p in plasma membrane of CAF2-1 (lane a), TPIPT1-1 (lane b), TPIPT1-3 (lane c), and TPIPT1-5 (lane
d). The PMs were prepared from C. albicans cells as described earlier (32). The Western blot analyses were done with anti-CDR1p polyclonal
antibody (1:500 dilution). The purity of the PM fraction was assessed by using anti-Pma1p polyclonal antibody (1:10,000 dilution). Pma1p is a
marker of the PM fraction (32). Immunoblots were visualized by using a chemiluminescence assay system (ECL kit; Amersham Biosciences).
(B) Fluorescence imaging by confocal microscope of strains TPWT-GFPCDR1 (a), TPD1-GFPCDR1 (b), TPD2-GFPCDR1 (c), and TPR1-
GFPCDR1 (d). Cells were grown overnight and were directly viewed on a glass slide under a 	100 oil-immersion objective on a Bio-Rad confocal
microscope. The fluorescence signal from strain TPWT-GFPCDR1 showed localization of Cdr1p on the plasma membrane. On depletion of the
sphingolipids, the GFP fluorescence from strains TPD1-GFPCDR1, TPD2-GFPCDR1, and TPR1-GFPCDR1 appeared to be concentrated inside
the cells, indicating poor localization of Cdr1p on the plasma membrane; the concentration was maximum inside TPD2-GFPCDR1 cells and in
the heterozygous mutant TPD1-GFPCDR1 was intermediate between those in WT and TPD2-GFPCDR1. This defect is reduced in the revertant
strain, TPR1-GFPCDR1, compared to that in TPD2-GFPCDR1. (C) Northern blot analyses of CDR1. Upper panel, equal CDR1 transcript levels
in strains TPWT-GFPCDR1 (lane a), TPD1-GFPCDR1 (lane b), TPD2-GFPCDR1 (lane c), and TPR1-GFPCDR1 (lane d); lower panel, loading
control to indicate equal gel loading of total RNA.
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served that among the ABC and MFS transporters of C. albi-
cans, the former are more sensitive to changes in the lipid
composition (27). To verify this observation, we monitored the
efflux of MTX, which is a specific substrate for CaMdr1p.
Similar intracellular levels of [3H]MTX in ipt1 mutant and WT
cells indicated no change in efflux of this substrate (Fig. 4C).
Of note, the MIC80 values of the IPT1 mutant cells for MTX
were also not different between WT and mutant cells (data not
shown).
The levels of Cdr1p in PM of IPT1mutant cells are reduced.
Since the functioning of Cdr1p appeared to be selectively af-
fected in TPIPT1-1 and TPIPT1-3 mutant cells, we explored if
it was due to the poor functioning of the protein or was due to
improper surface localization of the protein. For this, we
checked the expression of Cdr1p in the PM fractions of the
mutant cells. Interestingly, Western blotting results revealed
low levels of Cdr1p protein in PM of TPIPT1-3 (Fig. 5A, lane
c), while Northern analysis showed no difference in CDR1
transcript (Fig. 5C). In order to verify if the low level of efflux
protein in PM is indeed due to its poor localization, we exam-
ined the surface localization of Cdr1p in ipt1 mutant cells. For
this, we expressed Cdr1p as a GFP-tagged protein by integrat-
ing the CDR1-GFP cassette into the CDR1 locus by using the
SAT1 marker in both wild-type and ipt1 mutant cells (30). Of
note, SAT1 gene is a dominant selection marker derived from
the bacterial transposon Tn1825, which encodes streptothricin
acetyltransferase, which confers resistance to nourseothricin by
inactivating the antibiotic (30). It is evident from confocal
pictures (Fig. 5B, panel a) that while Cdr1p is properly local-
ized on the surface (rimmed appearance of the fluorescence)
in the WT Candida cells, the GFP fluorescence, in contrast,
appeared to be concentrated inside the ipt1 mutant cells (Fig.
5B, panels b and c). The rimmed fluorescence of Cdr1p-GFP
appeared to be partly restored in revertant strain TPIPT1-5
(Fig. 5B, panel d).
IPT1 mutants show enhanced NBD-SPH exchange. We had
earlier observed that in erg mutants of C. albicans larger
amounts of fluorescent NBD-SPH could be exchanged com-
pared to that in WT cells (28). In order to explore if changes
in sphingolipid composition had any effect within its local en-
vironment, we labeled Candida WT and IPT1 mutant cells with
fluorescent NBD-SPH, as described earlier (28). At 90 min
postlabeling, when NBD-SPH incorporation into Candida
membrane was found to be maximum (Fig. 6, inset), the cells
were washed and the NBD-SPH of the labeled cells was back-
extracted by using bovine serum albumin (28). The amount of
NBD-SPH backextracted from IPT1 mutant cells was much
larger in comparison to that backextracted from the WT cells
(Fig. 6). This would mean that the depletion of M(IP)2C and
the accumulation of MIPC in ipt1 mutant cells results in the
disruption of the interactions between M(IP)2C, MIPC, and
IPC and the other components of microdomains (particularly
ergosterol). Interestingly, the lower exchange of NBD-SPH in
the WT cells evidently indicates that M(IP)2C interacts with
ergosterol with a propensity higher than those of the other two
species of sphingolipids, namely, IPC and MIPC. Taken to-
gether, our earlier observations (28) as well as those from our
present study suggest that the changes in the composition of
either ergosterol or sphingolipids, which are raft constituents,
affect their close interactions.
Sphingolipid composition affects morphogenesis. Compared
to the wild-type Candida cells, the TPIPT1-1 and TPIPT1-3
mutants were unable to make long hyphal filaments in the
presence of serum or N-acetyl D-glucosamine (Fig. 7). The
filamentous growth from mature colony borders of cells
plated on solid Spider and SLAD medium plates was also
reduced in the TPIPT1-1 and TPIPT1-3 mutants. The mor-
phogenesis defect could partially be restored in TPIPT1-5
when it was reconstituted with a single functional copy of
the gene (Fig. 7).
FIG. 6. Postlabeling transbilayer exchange of NBD-SPH in the C. albicans wild type and IPT1 mutants. Cells were labeled with NBD-SPH
(inset) and then backexchanged with 2% bovine serum albumin, as described in Materials and Methods. The graph depicts data for the 90-min
time point, at which the maximum backexchanged fluorescence in the supernatant was recovered. The values are the means (indicated by the error
bars)  standard deviations of three independent experiments.
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DISCUSSION
The present study exploits the sphingolipid biosynthetic
pathway to show that any change in sphingolipid composition
leads to increased drug sensitivity and morphological defects in
C. albicans cells. We show that the change in sphingolipid
composition caused by disruption of its biosynthetic gene,
IPT1, led to the improper surface localization of a major ABC
drug efflux protein, Cdr1p. The inability of ipt1 mutant cells to
efflux drugs appeared to be the main cause of the increased
drug sensitivities of these cells. However, the impaired plasma
membrane barrier function (increased passive diffusion) due to
the altered sphingolipid composition may also contribute to
enhanced sensitivity to drugs (data not shown). Similar to
Saccharomyces cerevisiae, homozygous IPT1 disruptants of
Candida albicans had increased resistance to calcium chloride
(data not shown). It seems that sphingolipid metabolism in
yeast cells is linked to calcium homeostasis or is regulated by
the calcium ion concentration (8). Interestingly, changes in the
compositions of sphingolipids had a selective effect on the
functioning of the efflux pump proteins. For example, the efflux
of MTX, which is a specific substrate of an MFS drug efflux
protein, CaMdr1p (20), remained largely unaffected in IPT1
mutant cells.
Membrane sphingolipids and ergosterol are important sub-
sets of lipids and are part of distinct domains known as mem-
brane rafts (4, 16). Of note, since the total sphingolipid content
in ipt1 mutant cells remained unchanged, it can be speculated
that of the three species of sphingolipids, namely, IPC, MIPC,
and M(IP)2C, M(IP)2C probably has a greater propensity to
interact with ergosterol within microdomains of the plasma
membrane. That ipt1 mutants lacking M(IP)2C had larger
amounts of exchangeable NBD-tagged sphingolipid available
than the WT supports the contention presented above (Fig. 6).
It appears that the depletion of M(IP)2C and the accumulation
of MIPC in the ipt1 mutant cells result in the disruption of their
interactions with ergosterol, which leads to the greater ex-
FIG. 7. Phenotypic responses of the IPT1 mutant strains under different hypha-inducing conditions. (A and B) Colony morphologies on solid
Spider and SLAD plates, respectively; (C and D) the induction of filamentation in liquid media in response to N-acetyl-D-glucosamine and serum,
respectively, in the WT and strains TPIPT1-1, TPIPT1-3, and TPIPT1-5.
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changeability of NBD-SPH. This supports our earlier observa-
tion, in which we found that depletion of ergosterol also re-
sulted in enhanced exchangeability of NBD-SPH (28).
While the changes in sphingolipid composition did not cause
a severe growth defect in IPT1 mutant cells, it did affect their
ability to form hyphae. Recent reports suggest the involvement
of sterol- and sphingolipid-enriched microdomains in hyphal
morphogenesis in C. albicans, wherein membrane lipid polar-
ization appears to contribute to the ability of this pathogen to
grow in a highly polarized manner to form hyphae (25). Our
results are in agreement with those of such reports, since we
also observed that disruption of ergosterol- and M(IP)2C-rich
domains in the plasma membranes of the IPT1 mutants results
in defective hyphal morphogenesis. It appears that not only is
there a close interaction between membrane raft constituents
and the drug susceptibilities of yeast cells but there is also a
well-coordinated control of their synthesis (27, 28, 34, 39). In
this context, it is pertinent to mention that Pdr1p and Pdr3p,
well-known Zn(II)-Cys6 transcription factors which regulate
pleiotropic drug resistance in Saccharomyces cerevisiae, also
target IPT1 (15). Whether such coordination of raft constitu-
ents and MDR genes exists in C. albicans cells remains to be
established. Nonetheless, our results do point toward a close
interaction between raft lipid constituents and drug suscepti-
bilities as well as morphogenesis in C. albicans.
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